Geron Corp (GERN)

[Joda]

From yahoo board

Spoke to Anna please read then BUY BUY BUY
In November 2012, Dr. Ayalew Tefferi (the “investigator”), of Mayo Clinic, initiated an investigator-sponsored clinical trial to evaluate imetelstat in patients
with myelofibrosis and other myeloid malignancies (the “Myelofibrosis IST”). Mayo Clinic has informed Geron Corporation (the “Company” or “Geron”) that
effective January 22, 2014, the Myelofibrosis IST has been closed to new patient enrollment, and that the remaining patients in the study will continue to
receive imetelstat treatment and be followed under the Myelofibrosis IST protocol. The Company believes that approximately 79 patients have been enrolled in
the Myelofibrosis IST, including nine patients with blast-phase myelofibrosis and nine patients with refractory anemia with ringed sideroblasts (“RARS”), a
subpopulation of myelodysplastic syndromes, and that approximately 20 patients have discontinued from the study since its inception.

I repeat this panic was for nothing imetelstat is the best and only hope that actually works for Myelofibrosis.


you only looking at the number 20 and ignoring the rest of the info?Based on this preliminary efficacy and safety data, the Company plans to initiate a Geron-sponsored, multi-center, Phase 2 clinical trial of imetelstat in patients with myelofibrosis in the first half of 2014. The Company also believes that the total accrued patients in the Myelofibrosis IST will be adequate for gathering additional and updated safety and efficacy data to support the imetelstat development program.The Company expects that the investigator will present at a future medical conference additional and updated safety and efficacy data, including longer-term durability, for those patients previously reported and for additional remaining patients in the Myelofibrosis IST.


"The Company expects that the investigator will present at a future medical conference additional and updated safety and efficacy data, including longer-term durability..."

It should be noted that Dr. Tefferi is a practicing physician and would not be attending conferences to unveil bad news on one of his studies...

Yet his conference schedule is pretty busy:

Scripps’ 34th Annual Conference: Clinical Hematology and Oncology 2014
February 16th, 2014
Myeloproliferative Disorders: JAK2 and Beyond
Ayalew Tefferi, MD

11th Annual Hematology Review
Saturday, March 8, 2014
Conrad Indianapolis Hotel
50 West Washington St.
Indianapolis, IN 462048:00 am - 5:00 pm
TOPICS/FACULTY

A full day of presentations by today’s leaders in hematology and hematology malignancies

St.Vincent Cancer Care invites you to Indianapolis for a full day of presentations by the nation’s top experts in hematology and hematology malignancies. Participants will have the opportunity to interact with these thought leaders in several panel discussions.

This annual hematology review is one of the most comprehensive, educational hematology conferences in the country. Our exceptional faculty will provide a concise and practical summary of the American Society of Hematology annual meeting, presenting the most current hematology research and clinical practice.

New for 2014: Satellite Nursing Symposium

CHAIRPERSONS
RUEMU BIRHIRAY, MD - Chair

St.Vincent Hospital; Partner and Vice President, Hematology Oncology of Indiana (Indianapolis)

MICHAEL WIEMANN, MD, FACP - Co-Chair

President, Providence Hospital, Executive Vice President West Region, St. John Providence Health System (Warren, Michigan)
AYALEW TEFFERI, MD

Myeloproliferative Disorders